New strategies in GVHD prophylaxis
Despite immunosuppressive therapy using cyclosporine (CsA) and prednisolone and methotrexate (MTX), the incidence for aGVHD grade II to IV after transplantation from HLA matched unrelated donors (MUD) is 78%, the incidence for grade III and IV 36%. Since GVHD contributes to morbidity and mortality a...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2000-05, Vol.25 Suppl 2 (S2), p.S16-S19 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S19 |
|---|---|
| container_issue | S2 |
| container_start_page | S16 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 25 Suppl 2 |
| creator | Kiehl, M G Shipkova, M Basara, N Blau, W I Fauser, A A |
| description | Despite immunosuppressive therapy using cyclosporine (CsA) and prednisolone and methotrexate (MTX), the incidence for aGVHD grade II to IV after transplantation from HLA matched unrelated donors (MUD) is 78%, the incidence for grade III and IV 36%. Since GVHD contributes to morbidity and mortality after MUD-BMT, a more effective prophylactic regimen is needed in order to prevent these transplant-associated complications. Recently, we described that mycophenolate mofetil (MMF, CellCept), an immunosuppressive agent successfully used for the prevention of acute rejection in renal allograft recipients, can safely and effectively be used for the treatment of aGVHD in hematopoietic stem cell transplantation. Information on the i.v. formulation of mycophenolic acid (MPA) is not yet available. Here we report on the i.v. formulation of MMF in hematopoietic stem cell recipients. MMF is effective in the prophylaxis of acute GVHD after stem cell transplantation; the optimal dosage needs further investigation. At the present time the relevance of measurement of plasma MPA concentrations on MMF dosage is not yet understood and further evaluation is required. |
| doi_str_mv | 10.1038/sj.bmt.1702346 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_754885055</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71290537</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-d58090a7c3583a8eb890333b89226d8dab764e90b1d30244247f2f10d15eea883</originalsourceid><addsrcrecordid>eNqF0U1Lw0AQBuBFFFurV48SKugpcfZ79yhVq1D0ol6XTbLRhKSp2QTtv3elPYignubyzDsML0LHGBIMVF34KkmbPsESCGViB40xkyLmVPBdNAYiVEyp0CN04H0FgBkDvo9GGDSlWMEYTe_de-T7zvbupXQ-KpfR_Pn2Klp17ep1XduP0h-ivcLW3h1t5wQ93Vw_zm7jxcP8bna5iDMGuo9zrkCDlRnlilrlUqWBUhoGISJXuU2lYE5DinMKhDHCZEEKDDnmzlml6ASdb3LD7bfB-d40pc9cXdulawdvJGdKceA8yLO_JSYaOJX_QiwFSKFJgKc_YNUO3TK8a4hgBHMZ8oKa_qqwEEIxLQJKNijrWu87V5hVVza2WxsM5qsz4ysTOjPbzsLCyTZ1SBuXf-ObkugnNhiN_A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216668496</pqid></control><display><type>article</type><title>New strategies in GVHD prophylaxis</title><source>MEDLINE</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kiehl, M G ; Shipkova, M ; Basara, N ; Blau, W I ; Fauser, A A</creator><creatorcontrib>Kiehl, M G ; Shipkova, M ; Basara, N ; Blau, W I ; Fauser, A A</creatorcontrib><description>Despite immunosuppressive therapy using cyclosporine (CsA) and prednisolone and methotrexate (MTX), the incidence for aGVHD grade II to IV after transplantation from HLA matched unrelated donors (MUD) is 78%, the incidence for grade III and IV 36%. Since GVHD contributes to morbidity and mortality after MUD-BMT, a more effective prophylactic regimen is needed in order to prevent these transplant-associated complications. Recently, we described that mycophenolate mofetil (MMF, CellCept), an immunosuppressive agent successfully used for the prevention of acute rejection in renal allograft recipients, can safely and effectively be used for the treatment of aGVHD in hematopoietic stem cell transplantation. Information on the i.v. formulation of mycophenolic acid (MPA) is not yet available. Here we report on the i.v. formulation of MMF in hematopoietic stem cell recipients. MMF is effective in the prophylaxis of acute GVHD after stem cell transplantation; the optimal dosage needs further investigation. At the present time the relevance of measurement of plasma MPA concentrations on MMF dosage is not yet understood and further evaluation is required.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/sj.bmt.1702346</identifier><identifier>PMID: 10933180</identifier><language>eng</language><publisher>England: Nature Publishing Group</publisher><subject>Acute Disease ; Adult ; Bone marrow ; Bone marrow transplantation ; Complications ; cyclosporin A ; Cyclosporins ; Disease prevention ; Dosage ; Female ; Graft rejection ; Graft vs Host Disease - prevention & control ; Graft-versus-host reaction ; Hematopoietic Stem Cell Transplantation - adverse effects ; Hematopoietic stem cells ; Histocompatibility antigen HLA ; Humans ; Immunosuppressive agents ; Immunosuppressive Agents - administration & dosage ; Immunosuppressive Agents - blood ; Injections, Intravenous ; Kidney transplantation ; Leukemia - therapy ; Male ; Methotrexate ; Middle Aged ; Morbidity ; Mud ; Mycophenolate mofetil ; Mycophenolic acid ; Mycophenolic Acid - administration & dosage ; Mycophenolic Acid - analogs & derivatives ; Mycophenolic Acid - blood ; Prednisolone ; Prophylaxis ; Prospective Studies ; Stem cell transplantation ; Stem cells ; Transplantation</subject><ispartof>Bone marrow transplantation (Basingstoke), 2000-05, Vol.25 Suppl 2 (S2), p.S16-S19</ispartof><rights>Copyright Nature Publishing Group May 2000</rights><rights>Macmillan Publishers Limited 2000.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-d58090a7c3583a8eb890333b89226d8dab764e90b1d30244247f2f10d15eea883</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10933180$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kiehl, M G</creatorcontrib><creatorcontrib>Shipkova, M</creatorcontrib><creatorcontrib>Basara, N</creatorcontrib><creatorcontrib>Blau, W I</creatorcontrib><creatorcontrib>Fauser, A A</creatorcontrib><title>New strategies in GVHD prophylaxis</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><description>Despite immunosuppressive therapy using cyclosporine (CsA) and prednisolone and methotrexate (MTX), the incidence for aGVHD grade II to IV after transplantation from HLA matched unrelated donors (MUD) is 78%, the incidence for grade III and IV 36%. Since GVHD contributes to morbidity and mortality after MUD-BMT, a more effective prophylactic regimen is needed in order to prevent these transplant-associated complications. Recently, we described that mycophenolate mofetil (MMF, CellCept), an immunosuppressive agent successfully used for the prevention of acute rejection in renal allograft recipients, can safely and effectively be used for the treatment of aGVHD in hematopoietic stem cell transplantation. Information on the i.v. formulation of mycophenolic acid (MPA) is not yet available. Here we report on the i.v. formulation of MMF in hematopoietic stem cell recipients. MMF is effective in the prophylaxis of acute GVHD after stem cell transplantation; the optimal dosage needs further investigation. At the present time the relevance of measurement of plasma MPA concentrations on MMF dosage is not yet understood and further evaluation is required.</description><subject>Acute Disease</subject><subject>Adult</subject><subject>Bone marrow</subject><subject>Bone marrow transplantation</subject><subject>Complications</subject><subject>cyclosporin A</subject><subject>Cyclosporins</subject><subject>Disease prevention</subject><subject>Dosage</subject><subject>Female</subject><subject>Graft rejection</subject><subject>Graft vs Host Disease - prevention & control</subject><subject>Graft-versus-host reaction</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Hematopoietic stem cells</subject><subject>Histocompatibility antigen HLA</subject><subject>Humans</subject><subject>Immunosuppressive agents</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Immunosuppressive Agents - blood</subject><subject>Injections, Intravenous</subject><subject>Kidney transplantation</subject><subject>Leukemia - therapy</subject><subject>Male</subject><subject>Methotrexate</subject><subject>Middle Aged</subject><subject>Morbidity</subject><subject>Mud</subject><subject>Mycophenolate mofetil</subject><subject>Mycophenolic acid</subject><subject>Mycophenolic Acid - administration & dosage</subject><subject>Mycophenolic Acid - analogs & derivatives</subject><subject>Mycophenolic Acid - blood</subject><subject>Prednisolone</subject><subject>Prophylaxis</subject><subject>Prospective Studies</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Transplantation</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqF0U1Lw0AQBuBFFFurV48SKugpcfZ79yhVq1D0ol6XTbLRhKSp2QTtv3elPYignubyzDsML0LHGBIMVF34KkmbPsESCGViB40xkyLmVPBdNAYiVEyp0CN04H0FgBkDvo9GGDSlWMEYTe_de-T7zvbupXQ-KpfR_Pn2Klp17ep1XduP0h-ivcLW3h1t5wQ93Vw_zm7jxcP8bna5iDMGuo9zrkCDlRnlilrlUqWBUhoGISJXuU2lYE5DinMKhDHCZEEKDDnmzlml6ASdb3LD7bfB-d40pc9cXdulawdvJGdKceA8yLO_JSYaOJX_QiwFSKFJgKc_YNUO3TK8a4hgBHMZ8oKa_qqwEEIxLQJKNijrWu87V5hVVza2WxsM5qsz4ysTOjPbzsLCyTZ1SBuXf-ObkugnNhiN_A</recordid><startdate>20000501</startdate><enddate>20000501</enddate><creator>Kiehl, M G</creator><creator>Shipkova, M</creator><creator>Basara, N</creator><creator>Blau, W I</creator><creator>Fauser, A A</creator><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20000501</creationdate><title>New strategies in GVHD prophylaxis</title><author>Kiehl, M G ; Shipkova, M ; Basara, N ; Blau, W I ; Fauser, A A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-d58090a7c3583a8eb890333b89226d8dab764e90b1d30244247f2f10d15eea883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Acute Disease</topic><topic>Adult</topic><topic>Bone marrow</topic><topic>Bone marrow transplantation</topic><topic>Complications</topic><topic>cyclosporin A</topic><topic>Cyclosporins</topic><topic>Disease prevention</topic><topic>Dosage</topic><topic>Female</topic><topic>Graft rejection</topic><topic>Graft vs Host Disease - prevention & control</topic><topic>Graft-versus-host reaction</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Hematopoietic stem cells</topic><topic>Histocompatibility antigen HLA</topic><topic>Humans</topic><topic>Immunosuppressive agents</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Immunosuppressive Agents - blood</topic><topic>Injections, Intravenous</topic><topic>Kidney transplantation</topic><topic>Leukemia - therapy</topic><topic>Male</topic><topic>Methotrexate</topic><topic>Middle Aged</topic><topic>Morbidity</topic><topic>Mud</topic><topic>Mycophenolate mofetil</topic><topic>Mycophenolic acid</topic><topic>Mycophenolic Acid - administration & dosage</topic><topic>Mycophenolic Acid - analogs & derivatives</topic><topic>Mycophenolic Acid - blood</topic><topic>Prednisolone</topic><topic>Prophylaxis</topic><topic>Prospective Studies</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kiehl, M G</creatorcontrib><creatorcontrib>Shipkova, M</creatorcontrib><creatorcontrib>Basara, N</creatorcontrib><creatorcontrib>Blau, W I</creatorcontrib><creatorcontrib>Fauser, A A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kiehl, M G</au><au>Shipkova, M</au><au>Basara, N</au><au>Blau, W I</au><au>Fauser, A A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New strategies in GVHD prophylaxis</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><addtitle>Bone Marrow Transplant</addtitle><date>2000-05-01</date><risdate>2000</risdate><volume>25 Suppl 2</volume><issue>S2</issue><spage>S16</spage><epage>S19</epage><pages>S16-S19</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><abstract>Despite immunosuppressive therapy using cyclosporine (CsA) and prednisolone and methotrexate (MTX), the incidence for aGVHD grade II to IV after transplantation from HLA matched unrelated donors (MUD) is 78%, the incidence for grade III and IV 36%. Since GVHD contributes to morbidity and mortality after MUD-BMT, a more effective prophylactic regimen is needed in order to prevent these transplant-associated complications. Recently, we described that mycophenolate mofetil (MMF, CellCept), an immunosuppressive agent successfully used for the prevention of acute rejection in renal allograft recipients, can safely and effectively be used for the treatment of aGVHD in hematopoietic stem cell transplantation. Information on the i.v. formulation of mycophenolic acid (MPA) is not yet available. Here we report on the i.v. formulation of MMF in hematopoietic stem cell recipients. MMF is effective in the prophylaxis of acute GVHD after stem cell transplantation; the optimal dosage needs further investigation. At the present time the relevance of measurement of plasma MPA concentrations on MMF dosage is not yet understood and further evaluation is required.</abstract><cop>England</cop><pub>Nature Publishing Group</pub><pmid>10933180</pmid><doi>10.1038/sj.bmt.1702346</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2000-05, Vol.25 Suppl 2 (S2), p.S16-S19 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_754885055 |
| source | MEDLINE; Nature; EZB-FREE-00999 freely available EZB journals; SpringerLink Journals - AutoHoldings |
| subjects | Acute Disease Adult Bone marrow Bone marrow transplantation Complications cyclosporin A Cyclosporins Disease prevention Dosage Female Graft rejection Graft vs Host Disease - prevention & control Graft-versus-host reaction Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic stem cells Histocompatibility antigen HLA Humans Immunosuppressive agents Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - blood Injections, Intravenous Kidney transplantation Leukemia - therapy Male Methotrexate Middle Aged Morbidity Mud Mycophenolate mofetil Mycophenolic acid Mycophenolic Acid - administration & dosage Mycophenolic Acid - analogs & derivatives Mycophenolic Acid - blood Prednisolone Prophylaxis Prospective Studies Stem cell transplantation Stem cells Transplantation |
| title | New strategies in GVHD prophylaxis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T23%3A48%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20strategies%20in%20GVHD%20prophylaxis&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Kiehl,%20M%20G&rft.date=2000-05-01&rft.volume=25%20Suppl%202&rft.issue=S2&rft.spage=S16&rft.epage=S19&rft.pages=S16-S19&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/sj.bmt.1702346&rft_dat=%3Cproquest_cross%3E71290537%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=216668496&rft_id=info:pmid/10933180&rfr_iscdi=true |